Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, to treat sickle cell disease (SCD). The trial aims to assess ...

Findings highlight the importance of infection prevention measures and personalized heart failure care.

The study is being sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institute of Health (NIH). Fostamatinib, marketed in the U.S. as TAVALISSE ...

One of CTRID's strategic objectives is to enhance the training of basic and clinical researchers. Our NIH/NHLBI T32 training grant entitled “Collaborative Research Training in Thrombosis and ...

This program is an NIH/NHLBI R25 funded 8-week program to introduce outstanding undergraduates to the exciting career options of being both a scientific investigator and a practicing physician.

The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle cell disease.

CLM reports grant funding from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI). She is a consultant for the nonprofit Biologics and Biosimilars Collective ...